Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 7/20 | 0.49 |
| ▸ | HSD17B2 | P37059 | 5/20 | 0.49 |
| ▸ | IKBKB | O14920 | 3/20 | 0.47 |
| ▸ | FAAH | O00519 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL381149 | 0.81 | IKBKB (0.53) | IKBKBFAAHDRD2DRD3KCNH2 | |
| SCHEMBL7063111 | 0.72 | PARP1 (0.52) | HSD17B1HSD17B2IKBKBPARP1HPGDS | |
| SCHEMBL27975665 | 0.71 | ALDH1A1 (0.42) | PARP1JAK2 | |
| SCHEMBL5898706 | 0.71 | IKBKB (0.63) | IKBKBJAK2JAK3 | |
| SCHEMBL13616901 | 0.70 | ALDH1A1 (0.47) | — | |
| Urea SCHEMBL28406941 | 0.70 | HSD17B1 (0.68) | HSD17B1HSD17B2PARP1HPGDSCYP3A4 | |
| SCHEMBL381258 | 0.70 | FAAH (0.47) | IKBKBFAAHDRD2DRD3KCNH2 | |
| SCHEMBL381429 | 0.70 | CSNK2A2 (0.46) | HSD17B1HSD17B2PARP1CYP3A4CYP2C19 | |
| SCHEMBL1789847 | 0.69 | BCAT2 (0.67) | HSD17B1HSD17B2IKBKBPARP1CYP3A4 | |
| SCHEMBL4118761 | 0.69 | MAPT (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252865-A1 | CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2012-10-04 | — | — | US | disclosed |
| EP-2408743-A1 | CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010105930-A1 | CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252865-A1 | CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | ACHE, CHRNA10, CHRNA5 | HSD17B1 3385/4885HSD17B2 3986/4885IKBKB 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.